share_log
Hi,
moomoo ID:0
Log Out
English
Back
  • English
  • 中文繁体
  • 中文简体

Acadia Pharmaceuticals Says US FDA Accepts NDA, Grants Priority Review to Trofinetide for Rett Syndrome

MT Newswires ·  09/12 20:54

08:53 AM EDT, 09/12/2022 (MT Newswires) -- Acadia Pharmaceuticals (ACAD) said Monday that the US Food and Drug Administration has accepted for filing the company's new-drug application of trofinetide for Rett syndrome.

The drugmaker said that the application has been granted priority review and given a prescription drug user fee act action date of March 12.

The new-drug application is backed by findings from a late-stage study that assessed the efficacy and safety of trofinetide compared with placebo in 187 girls and young women aged 5 to 20 years old with Rett syndrome.

Rett syndrome is a multisystem neurodevelopmental disorder that causes loss of language and hand function skills, as well as gait impairment and development of hand stereotypes. It happens in one out of every 10,000 to 15,000 female births worldwide, the company said.

The company's shares were up by approximately 1.3% in recent premarket activity.

Price: 17.65, Change: +0.27, Percent Change: +1.55

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.